Author archives: Zacks Equity Research

Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.

Allegion’s (ALLE) Q4 earnings reflect the impacts of supply-chain restrictions, shortages of components, high costs and expenses, and effective pricing. It predicts y/y growth in 2022 earnings.

BCC, COLM, DIOD, PATK, and TGH have been added to the Zacks Rank #1 (Strong Buy) List on February 15, 2022.

Robust performance by the Product and Service segments is driving Omnicell’s (OMCL) fourth-quarter top line.

While Iridium’s (IRDM) Q4 results are likely to reflect the positive impact of surging service revenues, rising operating expenses and increased lead time are likely to have dented margins.

Ecolab (ECL) delivered earnings and revenue surprises of 0.79% and 5.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Investors are optimistic about Thermo Fisher’s (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

The improved gas pricing scenario is likely to have aided Antero’s (AR) Q4 earnings.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Norsk Hydro ASA (NHYDY) could be a great choice. It is one of the several…

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.